Citadel Advisors
RLAY icon

Citadel Advisors’s Relay Therapeutics RLAY Stock Holding History

Citadel Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$260K Sell
26,100
-10,200
-28% -$91.3K ﹤0.01% 10807
2025
Q4 		$307K Buy
36,300
+26,000
+252% +$186K ﹤0.01% 10093
2025
Q3 		$53.8K Buy
+10,300
New +$39.3K ﹤0.01% 12159
2025
Q2 		– Sell
-21,800
Closed -$57.1K – 14673
2025
Q1 		$57.1K Buy
+21,800
New +$85.4K ﹤0.01% 12169
2024
Q4 		– Sell
-1,500
Closed -$10.6K – 15243
2024
Q3 		$10.6K Sell
1,500
-200
-12% -$1.49K ﹤0.01% 13194
2024
Q2 		$11.1K Sell
1,700
-2,500
-60% -$17.1K ﹤0.01% 13053
2024
Q1 		$34.9K Buy
4,200
+2,300
+121% +$22.4K ﹤0.01% 12537
2023
Q4 		$20.9K Sell
1,900
-5,400
-74% -$45.6K ﹤0.01% 12585
2023
Q3 		$61.4K Sell
7,300
-1,600
-18% -$17.2K ﹤0.01% 11501
2023
Q2 		$112K Sell
8,900
-16,200
-65% -$202K ﹤0.01% 10759
2023
Q1 		$413K Buy
25,100
+17,100
+214% +$307K ﹤0.01% 8698
2022
Q4 		$120K Sell
8,000
-163,800
-95% -$3.14M ﹤0.01% 10973
2022
Q3 		$3.84M Sell
171,800
-66,900
-28% -$1.47M ﹤0.01% 4325
2022
Q2 		$4M Buy
+238,700
New +$5.12M ﹤0.01% 4212
2021
Q4 		– Sell
-44,600
Closed -$1.41M – 14600
2021
Q3 		$1.41M Buy
+44,600
New +$1.5M ﹤0.01% 7262

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors's RLAY Position: Q1 2026 in Review

Citadel Advisors increased its Relay Therapeutics (RLAY) stake by 54% in Q1 2026, buying an estimated $556K and bringing the position to 176,265 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #6366.

Citadel Advisors first reported a position in RLAY in Q3 2020 and has held it in 21 quarters since. The position peaked at $20.6M in Q3 2024. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Citadel Advisors held 176,265 shares of Relay Therapeutics worth $1.75M as of Q1 2026.
  • Citadel Advisors bought 62,122 Relay Therapeutics shares in Q1 2026, an estimated $556K.
  • Relay Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6366 holding.
  • Citadel Advisors first reported a position in Relay Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Citadel Advisors's Relay Therapeutics position peaked at $20.6M in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.